Alberto Mendivil, MD
Gynecologic Oncology · Newport Beach, CANPI 1801097662
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (47.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 67.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $30,418 and has fallen 82.5% since, to $5,319 in 2025. Among gynecologic oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $786.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$45K
- AstraZeneca$8K
- AbbVie$7K
- GSK$4K
- Seagen Inc.$3K
- Medtronic$172
- plus $161 from 2 others
Across 98 payments — averaging $11,340 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$476K
- Merck$345K
- AbbVie$142K
- Pfizer$102K
- Karyopharm Therapeutics Inc.$29K
- Tesaro, Inc.$18K
What the payments were for
- Consulting fees$20,77731%
- Speaking & faculty fees$7,50011%
- Travel & lodging$4,1506%
- Food & beverage$2,8514%
- Education$32,10847%
- Gifts$2710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 60 | $45,489 |
| AstraZeneca | 7 | $7,606 |
| AbbVie | 8 | $7,402 |
| GSK | 5 | $4,256 |
| Seagen Inc. | 1 | $2,572 |
| Medtronic | 2 | $172 |
| Immunogen, Inc. | 1 | $136 |
| Merck | 2 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,658 in reported general payments places this provider in the 90th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $12,719 |
| Estradiol | 14 | $577 |
| Duloxetine Hcl | 11 | $364 |
| Prochlorperazine Maleate | 22 | $274 |
| Ondansetron Hcl | 28 | $174 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Newport Beach
- Lisa AbaidNewport Beach$13K
- John BrownNewport Beach$6K
- Tiffany BeckNewport Beach$5K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.